ST-2427 / Eli Lilly - LARVOL DELTA

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - P1 | N=24 | Terminated | Sponsor: SiteOne Therapeutics, Inc. | Active, not recruiting ➔ Terminated; strategic decision

Trial termination • Pain

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: SiteOne Therapeutics, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Enrollment closed • Trial completion date • Trial primary completion date • Pain

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: SiteOne Therapeutics, Inc.; N=18 ➔ 30; Trial completion date: Aug 2021 ➔ Dec 2021; Trial primary completion date: Jul 2021 ➔ Dec 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Pain

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: SiteOne Therapeutics, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Pain

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: SiteOne Therapeutics, Inc.; N=48 ➔ 18; Initiation date: Sep 2020 ➔ Mar 2021; Trial primary completion date: Feb 2021 ➔ Jun 2021

Clinical • Enrollment change • Trial initiation date • Trial primary completion date • Pain

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: SiteOne Therapeutics, Inc.

Clinical • New P1 trial • Pain

Coordination of las regulated virulence factors with Multidrug-Resistant and extensively drug-resistant in superbug strains of P. aeruginosa. (PubMed, Mol Biol Rep) - "Interestingly, 16 known sequence types (including ST108, ST260, ST217) and three novel STs (ST2452, ST2427, and ST2542) were characterized among the collected isolates, which are related to the virulence and resistance. In MDR-XDR strains, a strong correlation between lasI/R and the variants of antibiotic resistance genes was found. In conclusion, the pathogenicity of P. aeruginosa may increase the prevalence of antibiotic-resistant strains."

Journal • Immunology

SiteOne announces award of $5.3M federal grant from NIH/NIDA for the development of a novel non-opioid analgesic (PRNewswire) - "SiteOne Therapeutics....today announced that it has received a Notice of Award from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) for grant funding under the Helping to End Addiction Long-term, or the NIH HEAL Initiative, to support development of the Company's lead therapeutic candidate, ST-2427, a novel NaV1.7 sodium channel inhibitor for the treatment of acute post-operative pain."

Grant